Charles Mowbray is the Discovery Director at DNDi responsible for discovering and advancing new drug candidates into development. He gained both BSc and PhD degrees in chemistry from the University of Exeter and completed postdoctoral fellowships at the University of British Columbia and the University of Nottingham. He joined Pfizer in Sandwich, UK, in 1992 and spent 19 years working as a medicinal chemist and project leader across multiple diseases, target classes, and medicinal chemistry strategies from target selection through to clinical candidate delivery. He joined DNDi in 2011 and has worked extensively on infectious diseases, including kinetoplastid diseases, with a particular focus on leishmaniasis, Chagas disease, COVID-19, and Dengue. He is responsible for the drug discovery team and its activities including screening, hit-to lead, lead optimisation, and preclinical and nonclinical activities in support of the DNDi portfolio. He served as the Principal Investigator for ‘21st Century treatments for sustainable elimination of leishmaniasis’ as a strategic partnership with Wellcome. He also conceived the NTD Drug Discovery Booster consortium with eight global pharmaceutical companies. He serves as an expert advisor to organisations working on medicinal chemistry, neglected diseases, and global health projects, and he has contributed to the WHO Access to COVID-19 Therapeutics Accelerator (ACT-A). He is a Fellow of the Royal Society of Chemistry.